A Pilot Trial of Interpersonal Psychotherapy for the Treatment of Depression in Patients With Prostate, Colorectal, Lung and Pancreatic Cancer

Sponsor
New York State Psychiatric Institute (Other)
Overall Status
Terminated
CT.gov ID
NCT01940237
Collaborator
(none)
4
1
1
37
0.1

Study Details

Study Description

Brief Summary

There is now overwhelming evidence documenting the efficacy of psychotherapy in the treatment of depression in the general population. Surprisingly, however, given the high prevalence of depression in cancer patients, there are very few studies on the efficacy of psychotherapy in this population. Published studies of psychotherapy in cancer patients generally include patients with high heterogeneity of psychiatric diagnosis and frequently include patients without a psychiatric diagnosis, with the aim of preventing the appearance of a psychiatric disorder. This heterogeneity complicates the interpretation of the efficacy and specificity of these interventions. Specifically, the efficacy of psychotherapy for major depression in patients with cancer is unknown.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Psychotherapy
N/A

Detailed Description

Interpersonal psychotherapy (IPT) is a brief, manualized therapy that has shown efficacy in the treatment of major depressive disorder (MDD) in several controlled trials. This study will test the efficacy of IPT in a group of prostate, colorectal, lung and pancreatic cancer patients with a diagnosis of major depressive disorder.

We will test the efficacy of IPT using a variety of outcome measures at different time points of the treatment. Those scales will evaluate the patient's depressive symptoms, psychosocial functioning and quality of life. Patients that are deemed eligible for the study will have IPT for twelve weeks. Patients will receive twelve 50-minute sessions over 16 weeks. To facilitate access to treatment, sessions 1,2,3,4, 8 and 12 will be in person, while all others will in be person or over the telephone according to the patient's choice. Sessions will be audiotaped and periodically reviewed by experienced supervisors to assess therapist's adherence to IPT technique. This taping will be optional and is covered in a separate consent form. This pilot study is to prove feasibility and acceptability of IPT in this population and to show preliminary efficacy.

Study Design

Study Type:
Interventional
Actual Enrollment :
4 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Study Start Date :
Apr 1, 2012
Actual Primary Completion Date :
May 1, 2015
Actual Study Completion Date :
May 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Experimental: Interpersonal Psychotherapy (IPT)

Interpersonal psychotherapy (IPT) is a brief, manualized therapy that has shown efficacy in the treatment of major depressive disorder (MDD) in several controlled trials. This study will test the efficacy of IPT in a group of prostate, colorectal, lung and pancreatic cancer patients with a diagnosis of major depressive disorder.

Behavioral: Psychotherapy
Interpersonal psychotherapy in the treatment of major depressive disorder.

Outcome Measures

Primary Outcome Measures

  1. Change in Hamilton Depression Scale (HAMD-17) [baseline, and every fourth week till week 12.]

    10 to 15 minutes of mood assessment.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • A primary psychiatric diagnosis of Major Depressive Disorder as defined by DSM-IV

  • Diagnosis of prostate, colorectal, lung or pancreatic cancer (stage 1-4)

  • A score of 16 or above in the 17-item HAM-D (Hamilton depression scale)

  • Male or female ages 18-75.

  • Ability to give consent

  • English and/ or Spanish Speaking

Exclusion Criteria:
  • Lifetime history of psychosis or bipolar disorder

  • History of substance abuse or dependence in the three months prior to the study.

  • Current suicide risk.

  • Patients who have ever failed IPT in the context of cancer.

  • Patients who are receiving effective medication for depression

  • Patients with T3, T4 and THS abnormal values

Contacts and Locations

Locations

Site City State Country Postal Code
1 New York State Psychiatric Institute New York New York United States 10032

Sponsors and Collaborators

  • New York State Psychiatric Institute

Investigators

  • Principal Investigator: Carlos Blanco, MD, PhD, NYSPI - Columbia University Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
New York State Psychiatric Institute
ClinicalTrials.gov Identifier:
NCT01940237
Other Study ID Numbers:
  • 6397
First Posted:
Sep 12, 2013
Last Update Posted:
May 19, 2017
Last Verified:
May 1, 2017

Study Results

No Results Posted as of May 19, 2017